About Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories Limited is a global pharmaceutical company headquartered in Hyderabad, India, guided by the purpose “Good Health Can’t Wait.” Its portfolio spans active pharmaceutical ingredients (APIs), generic formulations including biosimilars, over‑the‑counter (OTC) products, innovative products, and custom pharmaceutical services, with a focus on key therapeutic areas such as gastrointestinal, cardiovascular and oncology. The company’s major markets include the USA, India, Russia & CIS, China, Brazil and Europe. It serves patients in 83 countries, with a workforce representing 57 nationalities.

Dr. Reddy’s operates principal research and development facilities in Telangana and Andhra Pradesh (India) and Cambridge (UK), and principal manufacturing facilities in Telangana, Andhra Pradesh and Himachal Pradesh (India), Cuernavaca‑Cuautla (Mexico) and Mirfield (UK). Its shares are listed on the Bombay Stock Exchange, National Stock Exchange, NSE IFSC and the New York Stock Exchange. As per the consolidated entity list, the Group comprises 55 subsidiaries (including step‑down subsidiaries).

Dr. Reddy’s Laboratories Limited Milestones 

Key milestones in the latest year include progress on abbreviated new drug applications (ANDAs): as of March 31, 2025, 73 ANDAs and 3 NDAs were pending approval with the US FDA; of these, 46 are Para IVs and the company believes 20 have “First‑to‑File” status.

Dr. Reddy’s Laboratories Limited’s Business Segments

• Reportable segments: Global Generics; Pharmaceutical Services and Active Ingredients (PSAI); and Others.
• Revenue mix (FY2025): Global Generics 88.9%; PSAI 10.4%; Others 0.7%.
• Within Global Generics, geography mix (FY2025): North America 44.6%; Europe 11.0%; India 16.5%; Emerging Markets 16.8%.

Dr. Reddy’s Laboratories Limited Key Management

• K Satish Reddy – Chairman
• G V Prasad – Co‑Chairman and Managing Director
• Erez Israeli – Chief Executive Officer
• M V Narasimham – Chief Financial Officer
• Archana Bhaskar – Chief Human Resource Officer
• Deepak Sapra – Chief Executive Officer, API and Services
• M V Ramana – Chief Executive Officer, Branded Markets (India and Emerging Markets)
• Milan Kalawadia – Chief Executive Officer, North America
• Patrick Aghanian – Chief Executive Officer, Europe Generics
• Sanjay Sharma – Head Global Operations
• Sushrut Kulkarni – Global Head – Integrated Product Development Organisation
• Dr. Jayanth Sridhar – Global Head of Biologics
• Krishna Venkatesh – Global Head of Quality & Pharmacovigilance
• Phanimitra B – Chief Digital and Information Officer

Latest Updates on Dr. Reddy’s Laboratories Limited

• Acquisition of Nicotinell and other leading Nicotine Replacement Therapy (NRT) brands, expanding the consumer healthcare footprint in Europe and beyond.
• Partnerships: nutrition venture with Nestlé in India; US rights for Cyclophosphamide from Ingenus; launch of Galvus (anti‑diabetes) in Russia .
• A 1:5 forward stock split became effective on October 28, 2024.
• Board annual retreat held from September 03, 2024 to September 05, 2024 in Pennsylvania, USA, to deliberate strategic matters and business unit plans.